Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
AbbVie, advice, Afrin, Agencia, agile, Akorn, alendronate, allergen, Allergenic, Alnylam, Amgen, amnestic, anniversary, API, aprepitant, Aquaflor, Arcoxia, Aspen, ASR, auction, Avelox, Banamine, Bank, Bedford, Ben, benzoate, bid, biosimilar, BMS, bolstering, bound, Brazilian, breadth, breakthrough, broadly, Byetta, Canan, capable, Caravello, Cerazette, Chilcott, Chinese, Clarinex, Claritin, Clostridium, Coccivac, cognitive, colorectal, Compact, Complimentary, concomitant, confident, confirmatory, Coppertone, Coricidin, cotransporter, coupled, creation, CRL, desloratadine, desogestrel, developmental, devoting, discrimination, discriminatory, disparate, Dulera, dust, ear, effectuate, EPO, ertapenem, ertugliflozin, Estrumate, etoricoxib, Eurofarma, Ezetrol, facilitate, Farma, Fast, fed, feed, fluroquinolone, follicular, follitropin, footprint, Forest, Fosamac, Fosavance, Francisco, Franklin, gastric, glargine, Glynn, Goldman, Grastek, HBP, HCl, HCV, heightened, hostile, house, Implanon, inconsistent, incorrect, Inegy, Interactive, intolerant, Invanz, ipilimumab, Jellema, Karachun, Kelli, kinase, Korea, lesser, Lotrimin, Love, lump, Marvelon, Maryland, mild, mobile, modality, Montana, moxifloxacin, multinational, Munter, Nacional, neck, Nobivac, nonproprietary, Nuflor, omarigliptin, Ono, Oxytrol, Paracox, parasiticide, perlmutter, philanthropic, platform, Pneumovax, policymaker, posaconazole, preempted, preemption, Primaxin, proactive, prodromal, proper, Proscar, Puregon, Ragwitek, Rebetol, recurrence, Remeron, repricing, Resflor, resignation, retaliation, retroactively, Revalor, revocation, revoke, Rita, rizatriptan, ROGER, Rosenberg, round, ruminant, salt, Samsung, San, Scheinberg, Sessner, sharpen, SICAD, Sirna, Slice, Spano, sponte, spun, St, staggered, sua, successor, sue, Supera, surrogate, suspension, Sweet, Sycrest, Taxpayer, Temodal, tildrakizumab, timeline, Timothy, Tinactin, toll, top, Track, triple, true, Trusopt, Unanski, unfiled, unrepatriated, vacate, vacated, valent, Varivax, verify, Victoza, Vigilancia, Warner, weekly, winding, Zegerid, Zilmax, Zocor, Zoely, Zuprevo
Removed:
air, alpha, anal, ANDA, andAquaflorantibiotic, andClarinex, andFosamax, andIntron, andPorcilisvaccine, andResearch, andVytorin, andZegerid, angiotensin, argument, ARIAD, asAeriusin, asEzetrol, asEzetroloutside, asFosamacin, asFosavancethroughout, asInegy, asInegyoutside, asNoncontrolling, asOther, asPuregon, assetsare, assetswere, atorvastatin, atrial, balancing, beende, body, butsua, captionIn, certainFosamaxproduct, cervical, commencing, commercializeSimponi, competitor, concerningVytorinand, Conservation, consolidatedIncome, constituted, consultation, conversion, convertible, Coppertonesun, CR, damage, diminution, disputed, dissolvable, downturn, dupont, dysplastic, enterprise, equipmentand, estrogen, factual, fibrillation, forCosoptwill, forMaxalt, forMaxaltwill, forSimponi, forSingulair, FosamaxLitigation, Frameworkissued, Fred, fromAOCI, gastrointestinal, genital, glaucoma, Glenmark, Greek, groundwater, halted, Hamni, Hassan, HDL, heard, hemorrhage, Impax, inAccrued, inAccumulated, inAOCIand, incidence, includeCozaarandHyzaar, incomein, inDeferred, India, inducing, inEquity, informed, inInternal, inNoncontrolling, inOCI, inOther, inProperty, inRestructuring, inRosenberg, interestsin, intoSaleswhen, intracranial, intraocular, isde, JanuviaandJanumetfor, KIM, laropiprant, liabilitieswere, licensor, mammalian, marketCozaarandHyzaar, men, metastatic, Mexico, minimisand, mTOR, municipal, nameSycrest, naturally, negligence, niacin, Nuflorantibiotic, nuisance, NuvaRingMDL, ocular, ofAccumulated, ofBridionwere, ofCozaar, ofCozaarand, ofEmend, ofFollistim, ofFosamax, ofFosamaxand, ofFosamaxandFosamax, ofGardasil, ofJanumet, ofJanuvia, ofMaxalt, ofNasonex, ofNuvaRing, ofOCI, ofOther, ofPneumovax, ofPrimaxin, ofPropecia, ofSimponi, ofSingulair, ofSingulairin, ofTemodar, ofVioxx, ofVytorin, ofVytorinandZetia, ofVytorinandZetiain, ofZetia, onPrimaxinhave, onVioxxby, page, parent, participated, peripheral, phased, productsper, prostaglandin, purportedly, rapamycin, receivableandAccrued, reducedIncome, regained, remeasure, retiree, retirement, revascularization, sarcoma, secondary, selective, Sliceparasiticide, soil, sponsored, sponteordered, Standardsapplicable, subsidy, sugar, surgical, tafluprost, taxesby, taxeswould, TheBolescase, theFosamaxproduct, theNuvaRing, theNuvaRingMDL, thevioxx, thevioxxlitigation, thevioxxproduct, theVytorin, thrombin, throughOther, toAggrastat, toOther, toSalesmay, toSimponi, toVioxx, toVioxxin, toVytorin, TRACER, treating, unamortized, updated, vernakalant, virtue, vulvar, withdraw, withdrewVioxx, withinOCI, withinRestructuring, working, write, XR
Filing tables
Filing exhibits
- 10-K Annual report
- 3.2 EX-3.2: By-laws of Merck & Co., Inc. (Eff Feb 25 2014)
- 12 EX-12: Computation of Ratio of Earnings to Fixed Charges
- 21 Ex 21: Subsidiaries
- 23 EX-23: Consent of Independent Registered Public Accounting Firm
- 24.1 EX-24.1: Power of Attorney
- 24.2 EX-24.2: Certification of Board Resolution
- 31.1 EX-31.1: CEO Certification
- 31.2 EX-31.2: CFO Certification
- 32.1 EX-32.1: CEO Certification
- 32.2 EX-32.2: CFO Certification
- Download Excel data file
- View Excel data file
Related press release
MRK similar filings
Filing view
External links
Exhibit 24.1
POWER OF ATTORNEY
Each of the undersigned does hereby appoint GERALYN S. RITTER and BRUCE N. KUHLIK and each of them, severally, his/her true and lawful attorney or attorneys to execute on behalf of the undersigned (whether on behalf of the Company, or as an officer or director thereof, or by attesting the seal of the Company, or otherwise) the Annual Report on Form 10-K of Merck & Co., Inc. for the fiscal year ended December 31, 2013 under the Securities Exchange Act of 1934, including amendments thereto and all exhibits and other documents in connection therewith.
IN WITNESS WHEREOF, this instrument has been duly executed as of the 27th day of February 2014.
MERCK & CO., Inc.
/s/ Kenneth C. Frazier | Chairman, President and Chief Executive Officer | |
Kenneth C. Frazier | (Principal Executive Officer; Director) | |
/s/ Peter N. Kellogg | Executive Vice President and Chief Financial Officer | |
Peter N. Kellogg | (Principal Financial Officer) | |
/s/ John Canan | Senior Vice President Finance—Global Controller | |
John Canan | (Principal Accounting Officer) |
DIRECTORS
/s/ Leslie A. Brun | /s/ Carlos E. Represas | |
Leslie A. Brun | Carlos E. Represas | |
/s/ Thomas R. Cech | /s/ Patricia F. Russo | |
Thomas R. Cech | Patricia F. Russo | |
/s/ Thomas H. Glocer | /s/ Craig B. Thompson | |
Thomas H. Glocer | Craig B. Thompson | |
/s/ William B. Harrison, Jr. | /s/ Wendell P. Weeks | |
William B. Harrison, Jr. | Wendell P. Weeks | |
/s/ C. Robert Kidder | /s/ Peter C. Wendell | |
C. Robert Kidder | Peter C. Wendell | |
/s/ Rochelle B. Lazarus | ||
Rochelle B. Lazarus |